FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a new compound of formula (I) or a pharmaceutically acceptable salt thereof. Compound has the properties of a selective JAK3 inhibitor, exhibits high activity in suppressing the growth of human peripheral blood monocytes and oral absorption, and also exhibits activity when inhibiting IFN-γ in vivo. In general formula (I)
X is -CH = CH-, sulphur atom or oxygen atom; and n denotes integer from 0 to 2.
EFFECT: compound can be used for treating diseases involving JAK3, where the disease involving JAK3 is selected from a group consisting of psoriasis, graft versus host, multiple sclerosis, inflammatory bowel disease, systemic lupus erythematosus and rheumatoid arthritis.
16 cl, 2 dwg, 5 tbl, 31 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AZAINDOLE DERIVATIVE | 2015 |
|
RU2649575C1 |
| TRICYCLIC COMPOUND AND JAK INHIBITOR | 2015 |
|
RU2674262C2 |
| TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | 2012 |
|
RU2632870C2 |
| QUINOLYL PYRROLE PYRIMIDYL CONDENSED COMPOUND OR SALT THEREOF | 2013 |
|
RU2581039C1 |
| SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS | 2013 |
|
RU2666538C2 |
| CONDENSED QUINOLINE DERIVATIVE AND USE THEREOF | 2005 |
|
RU2384571C2 |
| HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | 2010 |
|
RU2615130C2 |
| NOVEL IMIDAZOOXAZINE COMPOUND OR SALT THEREOF | 2012 |
|
RU2578608C2 |
| EGFR INHIBITOR | 2021 |
|
RU2817044C1 |
| BROMDOMAIN INHIBITORS | 2012 |
|
RU2671571C1 |
